Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Superficial Bladder Cancer Clinical Trial

Official title:

Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00595088
• Other study ID #: BC-07-01.CTIL
• Status: Completed
• Phase: Phase 2
• Start date: January 2008
• Est. completion date: January 2013

Study information

• Verified date: April 2019
• Source: Anchiano Therapeutics Israel Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to assess the efficacy and safety of DTA-H19/PEI given as six intravesical instillations of 20 mg of plasmid DNA complexed with PEI into the bladder of patients with intermediate risk superficial bladder cancer [recurrent stages Ta (low or high grade)and T1, (low grade) transitional cell carcinoma (TCC)] who have failed prior intravesical therapies including either Bacillus Calmette-Guérin (BCG) or chemotherapy. The primary efficacy objective is to determine the effect of DTA-H19/PEI on the prevention of new tumors after the induction course of 6 weekly intravesical administrations of investigational product assessed 8 to 10 weeks after the start of treatment. Secondary objectives include assessing the ablative effect of DTA-H19/PEI on a marker tumor, safety assessed by the incidence and severity of adverse events, determining the long-term (46 weeks) continued rates of absence of bladder cancer, and time to tumor recurrence in those patients who had a complete response (CR) after the induction course.

Description:

DTA-H19, is a doubled stranded DNA plasmid that carries the gene for the diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter sequence. This is a Patient-Oriented, Targeted Therapy as DT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis in the tumor cell, enabling highly targeted cancer treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

To be eligible to participate in this study, patients must:

1. Provide written informed consent.

2. Have intermediate-risk recurrent superficial TCC of the bladder defined as Stage Ta (low or high grade) or T1 (but with penetration into no more than ½ of the lamina propria), low grade (grade 1 or grade 2), as confirmed by histopathology, and have not recurred within 3-months of a complete course of a prior acceptable therapy (i.e., 6-weekly intravesical administrations of BCG or standard adjuvant treatment with thiotepa, doxorubicin, epirubicin, valrubicin, or mitomycin C).

3. Have complete resection of all papillary tumors with the exception of a single superficial papillary tumor that is appropriate to be a marker tumor (<1 cm in diameter).

4. Have = 2 tumor and = 7 tumors visible during cystoscopy and no tumor larger than 3 cm in diameter. If only one tumor is present, it must be large enough to obtain a biopsy specimen adequate to determine the tumor stage and grade and leave a marker tumor.

5. Have at least one tumor specimen resected before the start of the study that was positive for H19 expression by ISH. H19 expression positive is defined as >= 60 % of the tumor cells in the specimen expressing H19 at a moderate staining intensity.

6. Have failed at least one prior standard intravesical treatment including chemotherapy with mitomycin C, thiotepa, valrubicin, doxyrubicin, or epirubicin, or immunotherapy with BCG. Failure after treatment with chemotherapy is defined as recurrent disease after at least one intravesical instillation of drug. Failure after treatment with BCG is defined as intolerance to treatment such that treatment was discontinued or after having received 6 or more BCG instillations there is recurrent or persistent disease 3 or more months after initiation of BCG treatment.

7. Have a Karnofsky's performance status of greater than or equal to 60%.

8. Have adequate bone marrow reserve: Hemoglobin > 10 g/dL, WBC greater than or equal to 3000/mm3, and platelets > 100,000 /mm3.

9. Have adequate renal function with serum creatinine < 1.5 x the laboratory upper limit of normal (ULN).

10. Have adequate liver function with serum biliru¬bin, AST/SGOT and ALT/SGPT < 2 times the laboratory ULN.

11. Be at least 18 years of age.

12. If male, agree to use a condom, if sexually active, and if female, agree to practice one of the acceptable methods of birth control or be surgically sterile or postmenopausal (greater than 1 year post last menstrual cycle.

Exclusion Criteria:

To be eligible to participate in this study, patients must not:

1. Have current diagnosis or history of Stage T1 (high grade) or Stage T2 or higher or CIS.

2. Have severe concomitant disease that might limit compliance or completion of the protocol.

3. Have a tumor in a diverticulum, in the prostatic urethra, or covering the ureteral orifice.

4. Have any other malignancy that might impact 5-year survival or might be potentially confused with TCC.

5. Have congenital or acquired immune deficiencies.

6. Be receiving cytotoxic drugs or corticosteroids.

7. Have received intravesical therapy within 8 weeks prior to study entry.

8. Have received radiation therapy for their bladder cancer at any time or any other conditions including pelvic irradiation for any condition within 4 months prior to study entry.

9. Have active infections (including urinary tract infections) defined as viral, bacterial, or fungal infections requiring therapy, HIV-positive status, concurrent febrile illness, or gross hematuria.

10. Have biopsy, TUR, or traumatic catheterization within 14 days of start of treatment.

11. If female, be pregnant or breast feeding.

12. Have participated in any therapeutic research study within the last 8 weeks.

13. Have participated in any other gene therapy study including patients who have received DTA-H19/PEI in the past.

Related Conditions & MeSH terms

• Superficial Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Biological:
• BC-819/PEI
Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.

Locations

Country	Name	City	State
Israel	Bnai Zion Medical Center	Haifa
Israel	Edith Wolfson Medical Center	Holon
Israel	Hadassah and Hebrew University Medical Center	Jerusalem
Israel	Meir Medical Center	Kfar Saba
Israel	Assaf Harofeh	Zrifin
United States	BCG Oncology	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Anchiano Therapeutics Israel Ltd.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Tumor Response Defined as the Absence of New Tumors	Tumor response evaluated at week 9 (range 8-10 weeks) during the first post induction course treatment cystoscopy or TUR of suspiciaous lesions	9 Weeks
Secondary	Time to Tumor Recurrence	The Time to Tumor Recurrence is defined as the interval between the date of the final tumor resection before the start of study treatments to the date when the cystoscopy was performed in which it was confirmed by histopathology that any suspicious lesions that were observed, were TCC of the bladder with the exception of the continued presence of the marker tumor at Week 9	46 Weeks
Secondary	Ablative Effect on a Marker Tumor	Complete disappearance of marker lesion	9 weeks